DBV Technologies (NASDAQ:DBVT) Posts Quarterly Earnings Results, Misses Expectations By $4.24 EPS

DBV Technologies (NASDAQ:DBVT) announced its earnings results on Thursday. The company reported ($4.43) EPS for the quarter, missing the consensus estimate of ($0.19) by ($4.24), FiscalAI reports. DBV Technologies had a negative return on equity of 295.58% and a negative net margin of 2,273.91%.

DBV Technologies Stock Down 0.3%

DBVT stock traded down $0.06 during midday trading on Thursday, reaching $20.21. The company’s stock had a trading volume of 200,324 shares, compared to its average volume of 345,987. The business’s 50-day simple moving average is $21.57 and its 200-day simple moving average is $17.12. DBV Technologies has a 52 week low of $3.91 and a 52 week high of $26.18. The stock has a market cap of $1.13 billion, a PE ratio of -3.91 and a beta of -0.97.

Analyst Ratings Changes

Several brokerages have recently commented on DBVT. HC Wainwright set a $40.00 target price on DBV Technologies in a report on Thursday, December 18th. Cantor Fitzgerald set a $48.00 price target on shares of DBV Technologies in a report on Wednesday, December 17th. Wall Street Zen raised DBV Technologies from a “sell” rating to a “hold” rating in a report on Sunday, February 8th. Weiss Ratings reissued a “sell (e+)” rating on shares of DBV Technologies in a research note on Monday, December 29th. Finally, Citigroup reaffirmed an “outperform” rating on shares of DBV Technologies in a research note on Wednesday, December 17th. Two equities research analysts have rated the stock with a Strong Buy rating, four have assigned a Buy rating, one has issued a Hold rating and two have assigned a Sell rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $38.25.

Institutional Investors Weigh In On DBV Technologies

Several large investors have recently bought and sold shares of the company. Artisan Partners Limited Partnership lifted its position in shares of DBV Technologies by 6,273.4% in the fourth quarter. Artisan Partners Limited Partnership now owns 3,309,055 shares of the company’s stock worth $63,435,000 after purchasing an additional 3,257,135 shares in the last quarter. Siren L.L.C. bought a new stake in DBV Technologies during the fourth quarter worth about $35,606,000. Vivo Capital LLC raised its holdings in DBV Technologies by 133.4% during the fourth quarter. Vivo Capital LLC now owns 2,461,626 shares of the company’s stock worth $47,189,000 after acquiring an additional 1,407,120 shares in the last quarter. Adage Capital Partners GP L.L.C. acquired a new position in DBV Technologies during the second quarter valued at approximately $9,659,000. Finally, MPM Bioimpact LLC acquired a new position in DBV Technologies during the second quarter valued at approximately $9,649,000. Institutional investors own 71.74% of the company’s stock.

DBV Technologies Company Profile

DBV Technologies SA is a clinical-stage biopharmaceutical company engaged in developing immunotherapies for allergic diseases. The company specializes in epicutaneous immunotherapy, leveraging its proprietary Viaskin platform to deliver biologically active compounds across intact skin without needles or injections. Through this approach, DBV aims to modulate patients’ immune response to specific allergens, offering a potentially safer and more convenient alternative to traditional therapies.

The company’s lead product candidate, Viaskin Peanut, is designed for the treatment of peanut allergy in children and adolescents.